| Stereochemistry | ABSOLUTE |
| Molecular Formula | C49H55N9O7 |
| Molecular Weight | 882.0171 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1(CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C)C2=NC=C(N2)C3=CC4=C(C=C3)N5[C@@H](OC6=C(C=CC(=C6)C7=CN=C(N7)[C@]8([H])CCCN8C(=O)[C@@H](NC(=O)OC)C(C)C)C5=C4)C9=CC=CC=C9
InChI
InChIKey=BVAZQCUMNICBAQ-PZHYSIFUSA-N
InChI=1S/C49H55N9O7/c1-27(2)41(54-48(61)63-5)45(59)56-20-10-14-37(56)43-50-25-34(52-43)30-17-19-36-32(22-30)23-39-33-18-16-31(24-40(33)65-47(58(36)39)29-12-8-7-9-13-29)35-26-51-44(53-35)38-15-11-21-57(38)46(60)42(28(3)4)55-49(62)64-6/h7-9,12-13,16-19,22-28,37-38,41-42,47H,10-11,14-15,20-21H2,1-6H3,(H,50,52)(H,51,53)(H,54,61)(H,55,62)/t37-,38-,41-,42-,47-/m0/s1
| Molecular Formula | C49H55N9O7 |
| Molecular Weight | 882.0171 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Elbasvir is an inhibitor of the Hepatitis C Virus (HCV) Non-Structural protein 5A (NS5A). Elbasvir was approved by the FDA in January 2016 for the treatment of hepatitis C. It was developed by Merck and completed Phase III trials, used in combination with the NS3/4A protease inhibitor grazoprevir under the trade name Zepatier. Zepatier is indicated for treatment of chronic
HCV genotype 1 or 4 infection in adults.
Originator
Approval Year
Doses
Sourcing
PubMed
Patents
Sample Use Guides
ZEPATIER is a two-drug, fixed-dose combination product containing 50 mg of elbasvir and 100 mg
of grazoprevir in a single tablet. The recommended dosage of ZEPATIER is one tablet taken orally once
daily with or without food. ZEPATIER is used in combination with
ribavirin in certain patient populations
Route of Administration:
Oral
